Use of avpr1a agonists
AssigneesViage Therapeutics Inc., Kyoto University
InventorsIgor D. Grachev, Sooin Hwang, Takahide Koda, Harald K. Murk, Takashi Nishida, Kousaku Ohinata, Dirk E. Smith, Steven August Smith, Kohei Kawano
Life of this patent
Estimating the term…
Abstract
AVPR1A agonists for use in treating a subject suffering from or at risk of (i) a disease or disorder of the nervous system or (ii) an inflammatory disease or disorder, or (b) improving sleep in a subject or (c) improving cognition in a subject.
Claims102
A method of (a) treating a subject suffering from or at risk of (i) a disease or disorder of the nervous system or (ii) an inflammatory disease or disorder, or (b) improving sleep in a subject or (c) improving cognition in a subject, comprising administering to the subject a therapeutically effective amount of an arginine vasopressin receptor 1A (AVPR1A) agonist, optionally wherein the AVPR1 agonist is an AVPR1A agonist described herein.
A method of (a) treating a subject suffering from or at risk of (i) a disease or disorder of the nervous system or (ii) an inflammatory disease or disorder, or (b) improving sleep in a subject or (c) improving cognition in a subject, comprising administering to the subject a therapeutically effective amount of an agent comprising a means for agonizing arginine vasopressin receptor 1A (AVPR1A).
The method of any one of claims 14 to 16, wherein the treating comprises improving or slowing progression of one or more negative symptoms of schizophrenia or psychosis.
The method of any one of claims 1 to 17, wherein the treating comprises improving or slowing progression of one or more negative symptoms of a disease or disorder of the central nervous system.
A method of treating a subject suffering from or at risk of Alzheimer's Disease or Parkinson's Disease comprising administering to the subject a therapeutically effective amount of a vasopressin analog or a pharmaceutically acceptable salt thereof.
A method of improving cognition in a subject comprising administering to the subject a therapeutically effective amount of a vasopressin analog or a pharmaceutically acceptable salt thereof.
A method of improving sleep in a subject comprising administering to the subject a therapeutically effective amount of a vasopressin analog or a pharmaceutically acceptable salt thereof.
A method of treating a subject suffering from or at risk of depression in a subject comprising administering to the subject a therapeutically effective amount of a vasopressin analog or a pharmaceutically acceptable salt thereof.
Use of an AVPR1A agonist in the manufacture of a medicament for treating any disease or disorder described herein.
Dependencies are inferred from the claim text.